A Simulation Model for Estimating Direct Costs of Type 1 Diabetes Prevention Jarmo HahlTuula SimellOlli Simell Original Research Article 22 September 2012 Pages: 295 - 303
Cost Effectiveness of Alendronate (Fosamax®) for the Treatment of Osteoporosis and Prevention of Fractures Olof JohnellBengt JönssonDennis Black Original Research Article 22 September 2012 Pages: 305 - 314
The Cost Effectiveness of Two New Antiepileptic Therapies in the Absence of Direct Comparative Data Ben A. van HoutDennis D. GagnonAnthony O’Hagan Original Research Article 22 September 2012 Pages: 315 - 326
Resource Utilisation and Cost Analysis of Memantine in Patients with Moderate to Severe Alzheimer’s Disease Anders WimoBengt WinbladHans-Jörg Möbius Original Research Article 22 September 2012 Pages: 327 - 340
Peginterferon α-2a (40kD) [Pegasys®] Improves HR-QOL Outcomes Compared with Unmodified Interferon α-2a [Roferon®-A] Jens RasenackStefan ZeuzemJesse Green Original Research Article 22 September 2012 Pages: 341 - 349
Cost Effectiveness of Nasal Budesonide versus Surgical Treatment for Nasal Polyps Fredrik BerggrenLeif Johansson Original Research Article 22 September 2012 Pages: 351 - 356
Factors Affecting UK Primary-Care Costs of Managing Patients with Asthma over 5 Years Roben Das GuptaJulian F. Guest Original Research Article 22 September 2012 Pages: 357 - 369